Our mission is to profoundly improve the treatment of patients with retinal vascular diseases and to transform the lives of those suffering from vision loss

Exonate is a Cambridge and Nottingham, UK-based biotechnology company developing novel, non-invasive, small-molecule therapeutics for patients with retinal vascular diseases leading to vision loss.

Our pipeline is built around inhibition of pro-angiogenic VEGF by influencing splice patterns, for the treatment of ophthalmic conditions caused by blood vessel growth, such as Diabetic Eye Disease and wet Age-Related Macular Degeneration (wet AMD).

Developed to penetrate to the back of the eye and prevent growth of blood vessels, our treatments for retinal diseases are being developed as eye drops, eliminating the need for monthly injections into the eye, laser surgery or use of steroids, improving patient wellbeing without sacrificing potency or permeability.

There is a large unmet need for a topical therapy for diabetic retinopathy and diabetic macular oedema that can treat the conditions earlier in the disease process. Our lead asset, EXN407, has the potential to be the first topical treatment for retinal vascular diseases, including diabetic retinopathy and diabetic macular oedema. EXN407 has shown encouraging signs of efficacy, alongside meeting all endpoints, in a Phase Ib/IIa trial in diabetic patients with retinal eye disease (diabetic macular oedema).

The Company is led by a highly experienced management team, and has a strong foundation of scientific expertise, with cross-disciplinary experience in medicine and drug development.